Semaglutide side effects: what the clinical trials reported

This review summarizes semaglutide side effects reported in clinical trials and current U.S. prescribing information as of November 17, 2026.

Trial readout6 min read

Key takeaway

In STEP 1, 44.2% of semaglutide participants reported nausea. The placebo rate was 17.4%. Diarrhea, vomiting and constipation were also more frequent in the semaglutide group. The current FDA label also describes gallbladder events, pancreatitis, kidney injury related to dehydration and other warnings.

At a glance

Article typeTrial readout
Main guideWhat is semaglutide? Structure, research and FDA status
Regulatory statusFDA-approved“It is an FDA-approved prescription drug (Ozempic, Wegovy, Rybelsus)” (Where to buy semaglutide)
ClassMetabolic & weight
Body systemsEndocrine & metabolism
Studies cited5 in this article · 29 across 14 articles on Semaglutide
ProductSemaglutide product page

Semaglutide side effects reported in clinical trials most often involved the gastrointestinal system. In the STEP 1 trial, nausea, diarrhea, vomiting and constipation were reported more frequently among semaglutide participants than placebo participants. Other studies and the current FDA label describe additional reported reactions and warnings.

Quick answer: The most frequently reported semaglutide side effects are nausea, diarrhea, vomiting, constipation and abdominal discomfort. Fatigue, headache, dizziness and hair loss also appear in U.S. prescribing information. Reported rates vary by product, indication and study population.

What did the semaglutide trials report?

The STEP 1 trial studied adults with overweight or obesity who did not have diabetes. It randomized 1,961 participants and assessed outcomes over 68 weeks. Gastrointestinal disorders were the most frequently reported adverse events in the semaglutide group. The trial reported nausea in 44.2% of participants, diarrhea in 31.5%, vomiting in 24.8% and constipation in 23.4%. The corresponding placebo rates were 17.4%, 15.9%, 6.6% and 9.5% (Wilding et al., 2021; ClinicalTrials.gov, NCT03548935).

The same trial reported at least one adverse event in 89.7% of semaglutide participants and 86.4% of placebo participants. Serious adverse events were reported in 9.8% and 6.4%, respectively. Adverse events led to treatment discontinuation in 7.0% of semaglutide participants and 3.1% of placebo participants. Gastrointestinal disorders led to discontinuation in 4.5% and 0.8%, respectively (Wilding et al., 2021).

These data come from adults with overweight or obesity who did not have diabetes. Other trials examined different populations and outcomes. For example, the SELECT study enrolled adults with established cardiovascular disease and overweight or obesity. A later safety analysis reported serious adverse events in 33.4% of semaglutide participants and 36.4% of placebo participants. Adverse events leading to permanent treatment discontinuation occurred in 16.6% and 8.2%, respectively. Gastrointestinal disorders accounted for much of the difference in discontinuation (SELECT safety analysis, 2025).

What are the most common semaglutide side effects?

The current Wegovy prescribing information lists nausea, diarrhea, vomiting, constipation and abdominal pain among common adverse reactions. It also lists fatigue, headache, dyspepsia, dizziness, abdominal distension, belching, flatulence and hair loss. The label states that adverse-reaction rates can differ across clinical studies and should not be compared casually across separate trials (DailyMed, Wegovy prescribing information).

Table 1

What are the most common semaglutide side effects

Adverse eventSemaglutide in STEP 1Placebo in STEP 1
Nausea44.2%17.4%
Diarrhea31.5%15.9%
Vomiting24.8%6.6%
Constipation23.4%9.5%
Any adverse event89.7%86.4%
Serious adverse event9.8%6.4%
Discontinuation due to adverse event7.0%3.1%

The STEP 1 investigators described the most common gastrointestinal events as typically mild to moderate and generally transient. More semaglutide participants than placebo participants discontinued treatment because of gastrointestinal events. That study-level description does not establish how an event will behave in another population or setting (Wilding et al., 2021).

Does semaglutide cause hair loss or tiredness?

Hair loss is included in the current Wegovy prescribing information. In pooled adult studies, hair loss was reported in 3.3% of participants receiving the product and 1.0% of placebo participants. The label says hair-loss adverse reactions were associated with weight reduction. It does not establish that every reported case was directly caused by semaglutide (DailyMed, Wegovy prescribing information).

Fatigue is also listed among common adverse reactions in the prescribing information. The label's patient-facing information lists tiredness alongside nausea, diarrhea, vomiting, constipation and other reported reactions. A single fatigue rate should not be applied across all semaglutide products and trial populations. The available tables cover different studies and indications (DailyMed, Wegovy prescribing information).

What serious events and warnings appear in the FDA label?

The Wegovy label includes warnings about acute pancreatitis and gallbladder disease. It also covers kidney injury related to volume depletion, hypoglycemia in certain settings, increased heart rate and pulmonary aspiration during anesthesia or deep sedation. These are label warnings, not findings that every participant experiences these events (DailyMed, Wegovy prescribing information).

In adult weight-reduction trials, the label reports cholelithiasis in 1.6% of participants receiving Wegovy and 0.7% of placebo participants. Cholecystitis was reported in 0.6% and 0.2%, respectively. The label notes that substantial or rapid weight reduction can increase gallstone risk. It also reports higher gallbladder disease incidence among treated participants after accounting for weight reduction (DailyMed, Wegovy prescribing information).

The label also describes pancreatitis as an observed event in patients treated with GLP-1 receptor agonists, including semaglutide. It includes a warning about severe or persistent abdominal pain. The label does not mean that every abdominal symptom is pancreatitis. It identifies a potential serious adverse reaction that has been observed and requires clinical evaluation (DailyMed, Wegovy prescribing information).

The boxed warning concerns thyroid C-cell tumors observed in rodents. The FDA label states that it is unknown whether semaglutide causes these tumors in humans. It also identifies contraindications involving a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. The distinction between animal findings and established human outcomes should remain explicit (DailyMed, Wegovy prescribing information).

Who was studied, and what is semaglutide's FDA status?

Semaglutide has been studied in several populations. STEP 1 examined adults with overweight or obesity without diabetes. The SELECT trial examined adults with established cardiovascular disease and overweight or obesity. Earlier diabetes trials examined adults with type 2 diabetes. These populations differ, so adverse-event rates from one study should not be assumed to apply directly to another (Wilding et al., 2021; SELECT safety analysis, 2025; Marso et al., 2016).

Semaglutide is the active ingredient in FDA-approved prescription products, including Wegovy and Ozempic. Each product has its own approved indications and prescribing information. The Wegovy label includes specific weight-reduction indications and other approved uses. The existence of approved semaglutide medicines does not mean that every product described as semaglutide has been reviewed or approved by the FDA (DailyMed, Wegovy prescribing information).

The FDA has warned that unapproved GLP-1 products do not undergo premarket review for safety, effectiveness and quality. Its notice discusses adverse-event reports involving compounded semaglutide and tirzepatide. It also states that semaglutide salt forms are different active ingredients from the semaglutide used in approved drugs (FDA, concerns with unapproved GLP-1 drugs).

Frequently asked questions

What are the most common semaglutide side effects?

The most frequently reported events include nausea, diarrhea, vomiting and constipation. The current Wegovy label also lists fatigue, headache, dizziness, abdominal discomfort and hair loss.

Does semaglutide cause hair loss?

Hair loss was reported in pooled adult Wegovy studies in 3.3% of treated participants and 1.0% of placebo participants. The label associates these reports with weight reduction.

Does semaglutide make people tired?

Fatigue appears among the common adverse reactions in the Wegovy prescribing information. The reported rate varies by study and product, so a single figure should not be generalized to all semaglutide use.

Is semaglutide FDA approved?

Semaglutide is the active ingredient in approved prescription products, including Wegovy and Ozempic. Each product has specific indications and its own FDA-approved prescribing information.

Are semaglutide side effects the same in every trial?

No. Trial populations, indications, follow-up periods and adverse-event definitions differ. The STEP 1 and SELECT populations, for example, were not the same.

What to know now

  • Gastrointestinal events were the most common adverse events in STEP 1 and remain prominent in the current Wegovy label.
  • Hair loss and fatigue appear in the label. The hair-loss reports were associated with weight reduction.
  • Approved prescription semaglutide products are distinct from unapproved or compounded products that have not undergone FDA premarket review.

What we’re watching

  • Future revisions to FDA prescribing information may change the current list of adverse reactions and warnings.
  • Continued follow-up from large cardiovascular and metabolic studies may add information about longer-term adverse events in different populations.

Vitrapep research material

Vitrapep sells semaglutide for laboratory research use only. It is not for human or veterinary use. The semaglutide research page and where-to-buy information provide related site information.

Semaglutide

Lyophilized Research use only

Specifications for the semaglutide sold for laboratory research. COA available with each lot.

View semaglutide specifications

Also in the library

More for endocrine & metabolism

All 38 compounds for endocrine & metabolism

Sources: Wilding 2021, The New England Journal of Medicine, 384; National Library of Medicine 2021; U.S. National Library of Medicine 2026; Lincoff 2023, The New England Journal of Medicine, 389; Ryan 2025, Obesity; Marso 2016, The New England Journal of Medicine, 375; Husain 2019, The New England Journal of Medicine, 381; U.S. Food and Drug Administration 2026; U.S. Food and Drug Administration 2026. All 9 citations

Back to the research library

References

  1. Wilding, J. P. H., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. The New England Journal of Medicine, 384, 989–1002. https://doi.org/10.1056/NEJMoa2032183
  2. National Library of Medicine. (2021). Effect and safety of semaglutide in subjects with overweight or obesity (STEP 1). ClinicalTrials.gov, NCT03548935. https://clinicaltrials.gov/study/NCT03548935
  3. U.S. National Library of Medicine. (2026). Wegovy (semaglutide) prescribing information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
  4. Lincoff, A. M., et al. (2023). Semaglutide and cardiovascular outcomes in obesity without diabetes. The New England Journal of Medicine, 389, 2221–2232. https://doi.org/10.1056/NEJMoa2307563
  5. Ryan, D. H., et al. (2025). Safety profile of semaglutide versus placebo in the SELECT study: A randomized controlled trial. Obesity. https://pubmed.ncbi.nlm.nih.gov/39948761/
  6. Marso, S. P., et al. (2016). Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. The New England Journal of Medicine, 375, 1834–1844. https://doi.org/10.1056/NEJMoa1607141
  7. Husain, M., et al. (2019). Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. The New England Journal of Medicine, 381, 841–851. https://doi.org/10.1056/NEJMoa1901118
  8. U.S. Food and Drug Administration. (2026). FDA's concerns with unapproved GLP-1 drugs used for weight loss. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
  9. U.S. Food and Drug Administration. (2026). Wegovy prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218316s005lbl.pdf